Biotech · Private company
Shanghai YingLi Pharmaceutical Co. Ltd.
Track this companyFree. Adds Shanghai YingLi Pharmaceutical Co. Ltd. to your Dealase workspace and tells you when its record changes.
Clinical trials41 recruiting or active
Pipeline programs4From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline4
- YL-15293Phase 2 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- YY-20394Phase 2 · Peripheral T/NK Cell Lymphoma (R/R PTCL)ClinicalTrials.gov · fetched Nov 12, 2026
- YL-13027Phase 1 · Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- YL-17231Phase 1 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials4
- Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRASPHASE1 · RECRUITING · started Oct 24, 2023ClinicalTrials.gov NCT06096974 · fetched Nov 12, 2026
- YL-13027 in Patients With Advanced Solid TumorsPHASE1 · UNKNOWN · started May 17, 2022ClinicalTrials.gov NCT05228600 · fetched Nov 12, 2026
- A Phase II Study of Linperlisib (YY-20394) in Patients With Relapsed or Refractory Peripheral T/NK Cell LymphomaPHASE2 · UNKNOWN · started May 1, 2022ClinicalTrials.gov NCT05274997 · fetched Nov 12, 2026
- A Phase 1/2, Study of YL-15293 in Subjects With Advanced Solid Tumors With a KRAS G12C MutationPHASE1_PHASE2 · UNKNOWN · started Nov 9, 2021ClinicalTrials.gov NCT05119933 · fetched Nov 12, 2026